These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 1412653)
1. Ivermectin does not reduce the burden of itching in an onchocerciasis endemic community. Whitworth JA; Luty AJ; Maude GH; Morgan D; Downham MD; Taylor DW Trans R Soc Trop Med Hyg; 1992; 86(3):281-3. PubMed ID: 1412653 [TBL] [Abstract][Full Text] [Related]
2. Maintaining compliance to ivermectin in communities in two West African countries. Whitworth JA; Alexander ND; Seed P; Thomas W; Abiose A; Jones BR Health Policy Plan; 1996 Sep; 11(3):299-307. PubMed ID: 10160375 [TBL] [Abstract][Full Text] [Related]
3. The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. Brieger WR; Awedoba AK; Eneanya CI; Hagan M; Ogbuagu KF; Okello DO; Ososanya OO; Ovuga EB; Noma M; Kale OO; Burnham GM; Remme JH Trop Med Int Health; 1998 Dec; 3(12):951-61. PubMed ID: 9892280 [TBL] [Abstract][Full Text] [Related]
4. The effect of 5 years of annual treatment with ivermectin (Mectizan) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic. Kennedy MH; Bertocchi I; Hopkins AD; Meredith SE Ann Trop Med Parasitol; 2002 Apr; 96(3):297-307. PubMed ID: 12061976 [TBL] [Abstract][Full Text] [Related]
5. Clinical and parasitological responses after up to 6.5 years of ivermectin treatment for onchocerciasis. Whitworth JA; Maude GH; Downham MD Trop Med Int Health; 1996 Dec; 1(6):786-93. PubMed ID: 8980590 [TBL] [Abstract][Full Text] [Related]
6. A community trial of ivermectin for onchocerciasis in Sierra Leone: clinical and parasitological responses to four doses given at six-monthly intervals. Whitworth JA; Morgan D; Maude GH; Luty AJ; Taylor DW Trans R Soc Trop Med Hyg; 1992; 86(3):277-80. PubMed ID: 1412652 [TBL] [Abstract][Full Text] [Related]
7. A community trial of ivermectin for onchocerciasis in Sierra Leone: clinical and parasitological responses to the initial dose. Whitworth JA; Morgan D; Maude GH; Downham MD; Taylor DW Trans R Soc Trop Med Hyg; 1991; 85(1):92-6. PubMed ID: 2068774 [TBL] [Abstract][Full Text] [Related]
8. Impact of five annual rounds of mass drug administration with ivermectin on onchocerciasis in Sierra Leone. Koroma JB; Sesay S; Conteh A; Koudou B; Paye J; Bah M; Sonnie M; Hodges MH; Zhang Y; Bockarie MJ Infect Dis Poverty; 2018 Apr; 7(1):30. PubMed ID: 29628019 [TBL] [Abstract][Full Text] [Related]
9. The impact of ivermectin on onchocerciasis in villages co-endemic for lymphatic filariasis in an area of onchocerciasis recrudescence in Burkina Faso. Nikièma AS; Koala L; Sondo AK; Post RJ; Paré AB; Kafando CM; Kambiré RS; Sow B; Bougouma C; Dabiré RK; Traoré S PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009117. PubMed ID: 33647010 [TBL] [Abstract][Full Text] [Related]
10. [Diagnostic image (82). A man with different leg colors. Onchocerciasis]. Verburg GP Ned Tijdschr Geneeskd; 2002 Mar; 146(13):616. PubMed ID: 11957381 [TBL] [Abstract][Full Text] [Related]
11. Effect of semiannual treatments of ivermectin on the prevalence and intensity of Onchocerca volvulus skin infection, ocular lesions, and infectivity of Simulium ochraceum populations in southern Mexico. Rodriguez-Perez MA; Rodriguez MH; Margeli-Perez HM; Rivas-Alcala AR Am J Trop Med Hyg; 1995 May; 52(5):429-34. PubMed ID: 7771609 [TBL] [Abstract][Full Text] [Related]
12. The burden of Onchocerca volvulus in Sudan. Mukhtar MM; Khier MM; Baraka OZ; Homeida MM Ann Trop Med Parasitol; 1998 Apr; 92 Suppl 1():S129-31. PubMed ID: 9861278 [TBL] [Abstract][Full Text] [Related]
13. The impact of five years of annual ivermectin treatment on skin microfilarial loads in the onchocerciasis focus of Asubende, Ghana. Alley ES; Plaisier AP; Boatin BA; Dadzie KY; Remme J; Zerbo G; Samba EM Trans R Soc Trop Med Hyg; 1994; 88(5):581-4. PubMed ID: 7992347 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of onchocerciasis and associated clinical manifestations in selected hypoendemic communities in Ghana following long-term administration of ivermectin. Otabil KB; Gyasi SF; Awuah E; Obeng-Ofori D; Atta-Nyarko RJ; Andoh D; Conduah B; Agbenyikey L; Aseidu P; Ankrah CB; Nuhu AR; Schallig HDFH BMC Infect Dis; 2019 May; 19(1):431. PubMed ID: 31101085 [TBL] [Abstract][Full Text] [Related]
15. Onchocerciasis situation in the Tukuyu focus of southwest Tanzania after ten years of ivermectin mass treatment. Mweya CN; Kalinga AK; Kabula B; Malley KD; Ruhiso MH; Maegga BT Tanzan Health Res Bull; 2007 Sep; 9(3):174-9. PubMed ID: 18087895 [TBL] [Abstract][Full Text] [Related]
16. Onchocerca volvulus: striking decrease in transmission in the Vina valley (Cameroon) after eight annual large scale ivermectin treatments. Boussinesq M; Prod'hon J; Chippaux JP Trans R Soc Trop Med Hyg; 1997; 91(1):82-6. PubMed ID: 9093638 [TBL] [Abstract][Full Text] [Related]
17. Improvement in severe onchocercal skin disease after a single dose of ivermectin. Pacqué M; Elmets C; Dukuly ZD; Muñoz B; White AT; Taylor HR; Greene BM Am J Med; 1991 May; 90(5):590-4. PubMed ID: 2029016 [TBL] [Abstract][Full Text] [Related]
18. The varied beneficial effects of ivermectin (Mectizan) treatment, as observed within onchocerciasis foci in south-eastern Nigeria. Anosike JC; Dozie IN; Ameh GI; Ukaga CN; Nwoke BE; Nzechukwu CT; Udujih OS; Nwosu DC Ann Trop Med Parasitol; 2007 Oct; 101(7):593-600. PubMed ID: 17877878 [TBL] [Abstract][Full Text] [Related]
19. Treatment of onchocerciasis with ivermectin (Province of Bururi, Burundi): parasitologic and clinical evaluation of different periodicities of treatment. Vyungimana F; Newell E Am J Trop Med Hyg; 1998 Nov; 59(5):828-31. PubMed ID: 9840606 [TBL] [Abstract][Full Text] [Related]
20. A community-based cross-sectional study of the epidemiology of onchocerciasis in unmapped villages for community directed treatment with ivermectin in Jimma Zone, southwestern Ethiopia. Dana D; Debalke S; Mekonnen Z; Kassahun W; Suleman S; Getahun K; Yewhalaw D BMC Public Health; 2015 Jul; 15():595. PubMed ID: 26130117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]